Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 22;10(11):1781.
doi: 10.3390/vaccines10111781.

Short-Term Adverse Effects Following Booster Dose of Inactivated-Virus vs. Adenoviral-Vector COVID-19 Vaccines in Algeria: A Cross-Sectional Study of the General Population

Mohamed Lounis  1 , Hani Amir Aouissi  2   3   4 , Samir Abdelhadi  5 , Mohammed Amir Rais  6 , Salem Belkessa  7 , Djihad Bencherit  7
Affiliations

Short-Term Adverse Effects Following Booster Dose of Inactivated-Virus vs. Adenoviral-Vector COVID-19 Vaccines in Algeria: A Cross-Sectional Study of the General Population

Mohamed Lounis et al. Vaccines (Basel). .

Abstract

COVID-19 booster vaccines have been adopted in almost all countries to enhance the immune response and combat the emergence of new variants. Algeria adopted this strategy in November 2021. This study was conducted to consider the self-reported side effects of COVID-19 booster vaccines by Algerians who were vaccinated with a booster dose of one of the approved inactivated-virus vaccines, such as BBIBP-CorV and CoronaVac, or one of the adenoviral-vector-based vaccines, such as Gam-COVID-Vac, AZD1222 and Ad26.COV2.S, and to determine the eventual risk factors. A cross-sectional study using an online self-administered questionnaire (SAQ) was conducted in Algeria between 28 April 2022, and 20 July 2022. A descriptive analysis of the 196 individuals who were included showed a nearly equal distribution of adenoviral- (52%) and inactivated-virus vaccines (48%) and of males (49.5%) and females (50.5%). The results showed that 74.7% of the studied population reported at least one local or systemic side effect. These side effects were more frequent among adenoviral-vector vaccinees (87.3%) than inactivated-virus vaccinees (60.6%) (sig. < 0.001). Injection site pain (40.3%), heat at the injection site (21.4%), and arm pain (16.3%) were the most common local side effects. These signs generally appeared in the first 12 h (73.3%) and generally lasted less than 24 h (32.8%). More interestingly, these signs differed from those that followed the administration of primer doses (48.5%) and were generally more severe (37%). The same observation was reported for systemic side effects, where the signs were especially most severe in the adenoviral-vaccinated group (49.4% vs. 20.8%; sig. = 0.001). These signs generally appeared within the first day (63.6%) and mostly disappeared before two days (50.8%), with fatigue (41.8%), fever (41.3%), and headache (30.1%) being the most common. Adenoviral-vector vaccinees (62.7%) were more likely to use medications to manage these side effects than were inactivated-virus vaccinees (45.7%) (sig. = 0.035) and paracetamol (48.5%) was the most used medication. Adenoviral-based vaccines were the types of vaccines that were most likely to cause side effects. In addition, being female increased the risk of developing side effects; regular medication was associated with local side effects among inactivated-virus vaccinees; and previous infection with COVID-19 was associated with systemic and local side effects among adenovirus-based vaccinees. These results support the short-term safety of booster vaccines, as has been reported for primer doses.

Keywords: Algeria; COVID-19; adenoviral-vector vaccines; booster; inactivated-virus vaccines; side effects; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Frequency of local side effects reported by the studied population.
Figure 2
Figure 2
Frequency of systemic side effects of the studied population.
See this image and copyright information in PMC

References

    1. Aouissi H.A., Kechebar M.S.A., Ababsa M., Roufayel R., Neji B., Petrisor A.-I., Hamimes A., Epelboin L., Ohmagari N. The Importance of Behavioral and Native Factors on COVID-19 Infection and Severity: Insights from a Preliminary Cross-Sectional Study. Healthcare. 2022;10:1341. doi: 10.3390/healthcare10071341. - DOI - PMC - PubMed
    1. World Health Organization (WHO) Coronavirus (COVID-19) Dashboard. [(accessed on 13 September 2022)]. Available online: https://covid19.who.int/
    1. Aouissi H.A., Hamimes A., Ababsa M., Bianco L., Napoli C., Kebaili F.K., Krauklis A.E., Bouzekri H., Dhama K. Bayesian Modeling of COVID-19 to Classify the Infection and Death Rates in a Specific Duration: The Case of Algerian Provinces. Int. J. Environ. Res. Public Health. 2022;19:9586. doi: 10.3390/ijerph19159586. - DOI - PMC - PubMed
    1. Alzarea A.I., Khan Y.H., Alatawi A.D., Alanazi A.S., Alzarea S.I., Butt M.H., Almalki Z.S., Alahmari A.K., Mallhi T.H. Surveillance of Post-Vaccination Side Effects of COVID-19 Vaccines among Saudi Population: A Real-World Estimation of Safety Profile. Vaccines. 2022;10:924. doi: 10.3390/vaccines10060924. - DOI - PMC - PubMed
    1. Hotez P.J., Batista C., Ben Amor Y., Ergonul O., Figueroa J.P., Gilbert S., Gursel M., Hassanain M., Kang G., Kaslow D.C., et al. Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. EClinicalMedicine. 2021;39:101053. doi: 10.1016/j.eclinm.2021.101053. - DOI - PMC - PubMed

LinkOut - more resources